Newbury Pharmaceuticals announced the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the first country in a Scandinavian registration procedure. Approvals in Sweden and Norway are expected to follow upon finalized national reviews. Liraglutide Pre-Filled Pen, a GLP-1 peptide drug that will be marketed under the brand name Milmiga®?, is a bioequivalent version ofVictoza pre-filled pen, indicated for the treatment of type 2 diabetes.

Victoza achieved sales exceeding EUR27 million in Scandinavia, as reported by DLMI.